Evaluation of the French Version of Screening Questionnaires for Autism and Asperger Syndrome: AQ, EQ and SQ

July 23, 2007 updated by: Groupe Francais d'Epidemiologie Psychiatrique

Evaluation of the French Version of Screening Questionnaires for Autism and Asperger Syndrome : Autism Spectrum Quotient (AQ) Empathy Quotient (EQ) and Systemizing Quotient (SQ)

Autism is considered as an invading disorder of the development. Asperger Syndrome (AS) is a particular form of autism and is difficult to diagnose. The Autism Spectrum Quotient (AQ) has been developed in order to measure the degree of autistic traits in autistic adolescent with normal intelligence (Baron-Cohen et al. 2001, 2006). AQ comprises 50 questions, with 5 groups of 10 questions assessing imagination, social skills, attention switching, attention to detail and communication skills. Each of these items scores 1 point if the respondent records abnormal or autistic like behaviour. The minimum score on the AQ is 0 and the maximum 50.

The principal objective of this study is to evaluate the accuracy of the French version of Autism Spectrum Quotient questionnaire.

Secondary objectives are to:

Evaluate if EQ and SQ can distinguish adolescents without psychiatric syndromes from those with classical autism or AS.

Evaluate if AQ, EQ and SQ can distinguish adolescents with psychiatric disorders from autistic adolescents.

Define the threshold of positivity for the 3 questionnaires.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

4 groups of participants will be screened with the questionnaires: Group 1: 50 adolescents with AS or high functioning autism (HFS) diagnosed by psychiatrists using established criteria and with an IQ >85.

Group 2: 50 adolescents with AS or classical autism diagnosed by psychiatrists using established criteria 70<IQ<84.

Group 3: 50 adolescents with psychiatric disorders. Group 4: Sample of 50 healthy adolescents selected randomly from 200. The questionnaires are given to the parents of adolescents during the first meeting. Parents are invited to send them back to the clinical investigation centre of Lyon (France).

Multicentre study: 8 clinical centres and 18 paediatricians

Study Type

Observational

Enrollment (Anticipated)

450

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

12 years to 18 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

Group 1 (AS/HFA) and 2 (AS/classic autism) :

  • Boys and girls aged 12 to 18
  • Patients with autism or Asperger syndrome according to the diagnostic criteria (ICD 10)
  • Patients receiving education in an ordinary school
  • IQ>70

Group 3 (adolescents with psychiatric disorders):

  • Boys and girls aged 12 to 18
  • Patients hospitalized on a psychiatric ward or at a psychiatrics patient visit or psychiatric consultation wit hout autistic syndrome
  • Patients receiving education in an ordinary school when not in hospital

Group 4 (adolescent without psychiatric syndrome):

  • Boys and girls aged 12 to 18
  • Patients receiving education in an ordinary school

Exclusion Criteria:

For all groups :

  • Problem with language or comprehension
  • Participants who have not given their consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Defined Population
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
1
50 adolescents with AS or high functioning autism (HFS) diagnosed by psychiatrists using established criteria and with an IQ >85.
Other: questionnaires

Primary outcome:

Autism Spectrum Quotient (AQ)

Secondary outcome measure:

Empathy quotient (EQ) Systemizing quotient (SQ) WISC III or WISC IV ADOS score ADI score
2
50 adolescents with AS or classical autism diagnosed by psychiatrists using established criteria 70<IQ<84.
Other: questionnaires

Primary outcome:

Autism Spectrum Quotient (AQ)

Secondary outcome measure:

Empathy quotient (EQ) Systemizing quotient (SQ) WISC III or WISC IV ADOS score ADI score
3
50 adolescents with psychiatric disorders but no autism syndrom.
Other: questionnaires

Primary outcome:

Autism Spectrum Quotient (AQ)

Secondary outcome measure:

Empathy quotient (EQ) Systemizing quotient (SQ) WISC III or WISC IV ADOS score ADI score
4
Sample of 50 healthy adolescents selected randomly from 200.
Other: questionnaires

Primary outcome:

Autism Spectrum Quotient (AQ)

Secondary outcome measure:

Empathy quotient (EQ) Systemizing quotient (SQ) WISC III or WISC IV ADOS score ADI score

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Groupe Francais d'Epidemiologie Psychiatrique

Collaborators

Joint Clinical Research Center

Investigators

  • Principal Investigator: Sabine Manificat, MDH, Centre Hospitalier Saint Jean de Dieu

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2007

Primary Completion

December 7, 2022

Study Completion (Anticipated)

July 1, 2009

Study Registration Dates

First Submitted

July 23, 2007

First Submitted That Met QC Criteria

July 23, 2007

First Posted (Estimate)

July 25, 2007

Study Record Updates

Last Update Posted (Estimate)

July 25, 2007

Last Update Submitted That Met QC Criteria

July 23, 2007

Last Verified

July 1, 2007

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Autisme AQ

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Autism

Clinical Trials on questionnaires

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe